Abbott signs Texas bill funding psychedelic ibogaine research and clinical trials for opioid use disorder and mental health conditions

Ibogaine research moves forward in Texas after Gov. Greg Abbott signed a $50 million bill aimed at bringing ibogaine into FDA-approved clinical trials. The legislation sets up a public-private partnership: state funding is paired with private investment from drug developers, and if ibogaine gets FDA approval, Texas would receive a share of revenue from the drug development process. The bill is framed as targeting opioid use disorder plus other neurological and mental health conditions, including PTSD, anxiety, and depression. The coverage also notes safety and pre-screening needs because ibogaine is linked to cardiac risks, and it references observational findings from veterans who sought ibogaine therapy in Mexico and reported being in the normal range after treatment.